Skip to content
Peptide research

Cagrilintide

Also known as NN9838 · AM833
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic amylin analog for significant weight loss, studied alone and with semaglutide in the fixed combination CagriSema. Human weight-loss evidence is strong, but claims of gentler GI tolerability than GLP-1 agonists are speculative. Gastrointestinal effects hit 41 to 63 percent of patients, and a theoretical thyroid cancer risk with limited long-term safety data remain unresolved. It is not FDA-approved.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Significant Weight Loss

    High

    The phase 2 trial showed 6.0–10.8% weight loss from baseline versus 3.0% with placebo; the highest cagrilintide dose outperformed liraglutide.

  • Appetite and Satiety Regulation

    Medium

    Appetite suppression is mechanism based, inferred from weight loss trials rather than directly measured in humans.

  • Improved GI Tolerability vs GLP-1 Agonists

    Low

    REDEFINE 1 directly randomized participants to cagrilintide, semaglutide, their combination, or placebo.

Evidence limits

Evidence Level
Strong

Cagrilintide has been evaluated in multiple Phase 1, Phase 2, and Phase 3 randomized controlled trials. The Phase 2 dose-finding trial (n=706) demonstrated dose-dependent weight loss up to 10.8% with the 4.5 mg dose. A Phase 1b trial (n=96) confirmed acceptable safety when co-administered with semaglutide 2.4 mg, with no pharmacokinetic interference. A Phase 2 trial in type 2 diabetes (n=92) showed CagriSema achieved 15.6% weight loss and 2.2% HbA1c reduction. The REDEFINE Phase 3 program demonstrated approximately 20-23% weight loss with CagriSema vs placebo. A systematic review and meta-analysis of 3 RCTs (n=430) confirmed CagriSema provides 9% additional weight loss over semaglutide alone with an acceptable safety profile. Evidence quality is rated strong based on multiple well-designed RCTs, though longer-term safety data beyond 68 weeks is still needed.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of MTC

    Absolute

    Personal/family history of MTC — semaglutide is contraindicated; cagrilintide has no approved prescribing label.

  • History of pancreatitis

    High

    Pancreatitis risk requires monitoring. Patients with prior pancreatitis should discuss risks carefully.

  • Severe gastroparesis

    High

    Amylin analogs slow gastric emptying. Pramlintide (same class) is contraindicated in gastroparesis.

  • Hypoglycemia unawareness

    High

    When co-administered with insulin, amylin analogs significantly increase severe hypoglycemia risk.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

Risk summary(11)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation, abdominal pain) affecting 41-63% of patients at therapeutic doses

    High
  • Injection site reactions including redness, swelling, and pain at the subcutaneous injection site

    Moderate
  • The MTC contraindication belongs to semaglutide labeling; it is not an approved cagrilintide-specific contraindication.

    Theoretical
  • Semaglutide is contraindicated in MEN2; cagrilintide-specific approved contraindications have not been established.

    Theoretical
  • Risk of hypoglycemia when combined with insulin or insulin secretagogues (sulfonylureas)

    Moderate
  • May exacerbate symptoms in patients with gastroparesis or delayed gastric emptying

    Moderate
  • Not evaluated in pregnant or lactating individuals; should be avoided unless clinically justified

    Moderate
  • Caution required in severe renal impairment (eGFR <30 mL/min/1.73 m2) due to insufficient safety data

    Low
  • Long-term safety data beyond 68 weeks is currently limited

    Moderate
  • Potential interaction with warfarin due to rapid weight loss affecting drug metabolism

    Theoretical
  • Higher vomiting rates observed with CagriSema combination (OR 9.57) compared to semaglutide alone

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.